AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial


Dobrowsky W., Huigol N. G. , Jayatilake R. S. , Kizilbash N., Okkan S. , Kagiya V. T. , ...More

RADIOTHERAPY AND ONCOLOGY, vol.82, no.1, pp.24-29, 2007 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 82 Issue: 1
  • Publication Date: 2007
  • Doi Number: 10.1016/j.radonc.2006.11.007
  • Title of Journal : RADIOTHERAPY AND ONCOLOGY
  • Page Numbers: pp.24-29

Abstract

Purpose: AK-2123, a nitrotriazole hypoxic cell sensitizer, has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage III and IV.